Overview

* Altimmune ( ALT ) Q3 revenue and net income beat analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting improved financial performance

* Company strengthens executive team with key appointments

Outlook

* Altimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025

* Company to hold End-of-Phase 2 meeting with FDA in Q4 2025

* Topline results from RECLAIM trial in AUD expected in 2026

Result Drivers

* Research and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $5,000 $600 (8

Revenue Analysts

)

Q3 EPS Beat -$0.21 -$0.27

(9

Analysts

)

Q3 Net Beat -$19.01 -$23.60

Income mln mln (8

Analysts

)

Q3 Beat -$20.86 -$25.50

Income mln mln (8

from Analysts

Operatio )

ns

Q3 Basic -$0.21

EPS

Q3 $20.86

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Altimmune Inc ( ALT ) is $18.00, about 79.2% above its November 5 closing price of $3.75

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)